Disparate clinical results for EGFR and HER2 targeted therapies in MIBC is most likely explained by the underlying heterogeneity of bladder cancer and the lack of adequate molecular descriptions of its molecular subtypes; the context in which the HER2 and EGFR targets operate [10]. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.